TY - JOUR
T1 - The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease
AU - Alzheimer's Disease Neuroimaging Initiative and Dementia Competence Network
AU - Louwersheimer, Eva
AU - Ramirez, Alfredo
AU - Cruchaga, Carlos
AU - Becker, Tim
AU - Kornhuber, Johannes
AU - Peters, Oliver
AU - Heilmann, Stefanie
AU - Wiltfang, Jens
AU - Jessen, Frank
AU - Visser, Pieter Jelle
AU - Scheltens, Philip
AU - Pijnenburg, Yolande A.L.
AU - Teunissen, Charlotte E.
AU - Barkhof, Frederik
AU - van Swieten, John C.
AU - Holstege, Henne
AU - Van der Flier, Wiesje M.
N1 - Funding Information:
The DCN study was funded by the German Federal Ministry for Education and Research (grant: 01GI0422 ).
Funding Information:
Eva Louwersheimer, Tim Becker, Johannes Kornhuber, Oliver Peters, Stefanie Heilman, Jens Wiltfang, Frank Jessen, Yolande A. L. Pijnenburg, John C. van Swieten, Henne Holstege report no conflicts of interest. Carlos Cruchaga receives support from the National Institutes of Health ( R01-NS085419 and R01-AG044546 ) and the Alzheimer's Association ( NIRG-11–200110 ). This research was conducted although Carlos Cruchaga was a recipient of a New Investigator Award in Alzheimer's disease from the American Federation for Aging Research. Carlos Cruchaga is a recipient of a Bright Focus Foundation Alzheimer's Disease Research Grant ( A2013359S ). Pieter Jelle Visser has served as a consultant or as an advisory board member for Myraid, Elan/Wyeth, Danone Research, Ipsen, Bristol-Myers Squibb, and Roche Diagnostics, received research support from Bristol-Myers Squibb , the European Union , Diagenic , and Innogenetics , and received speaker fees from Novartis and Lundbeck. Philip Scheltens has served as consultant for Wyeth-Elan, Genentech, Danone, and Novartis, and received funding for travel from Pfizer, Elan, Janssen, and Danone Research. Charlotte E. Teunissen has performed contract research for IBL and Probiodrug. Frederik Barkhof serves/has served on the advisory boards of Bayer-Schering Pharma, Sanofi-Aventis, Biogen Idec, TEVA, Merck-Serono, Novartis, Roche, Synthon BV, Jansen Research, Genzyme and received funding from the Dutch MS Society , EU-FP7 and has been a speaker at symposia organized by the Serono Symposia Foundation and Med Scape. Wiesje M. van der Flier has received funding and speaker honorarium from Boehringer Ingelheim ; all funds were paid to her institution.
Funding Information:
Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) ( National Institutes of Health grant U01 AG024904 ) and DOD ADNI (Department of Defense award number W81XWH-12-2–0012 ). ADNI is funded by the National Institute on Aging , the National Institute of Biomedical Imaging and Bioengineering , and through generous contributions from the following: Alzheimer's Association ; Alzheimer's Drug Discovery Foundation ; BioClinica ; Biogen Idec Inc ; Bristol-Myers Squibb Company ; Eisai Inc ; Elan Pharmaceuticals, Inc ; Eli Lilly and Company ; F. Hoffmann-La Roche Ltd and its affiliated company Genentech ; GE Healthcare ; Innogenetics ; IXICO Ltd. ; Janssen Alzheimer Immunotherapy Research & Development, LLC ; Johnson & Johnson Pharmaceutical Research& Development LLC ; Medpace, Inc ; Merck & Co, Inc ; Meso Scale Diagnostics, LLC ; NeuroRx Research ; Novartis Pharmaceuticals Corporation ; Pfizer Inc ; Piramal Imaging ; Servier ; Synarc Inc ; and Takeda Pharmaceutical Company . The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - We studied the association of SORL1 single-nucleotide polymorphisms genotypes with measures of pathology in patients with probable Alzheimer's disease (AD) using an endophenotype approach. We included (1) 133 patients from the German Dementia Competence Network (71 ± 8years; 50% females; Mini Mental State Examination [MMSE], 24 ± 3); (2) 83 patients from the Alzheimer's Disease Neuroimaging Initiative (75 ± 8years; 45% females; MMSE, 24 ± 2); and (3) 452 patients from the Amsterdam Dementia Cohort 66 ± 8years; 47% females; MMSE, 20 ± 5). As endophenotype markers we used cognitive tests, cerebrospinal fluid (CSF) biomarkers amyloid-beta, total tau (tau), tau phosphorylated at threonine 181, and hippocampal atrophy. We measured 19 SORL1 SNP alleles. Genotype-endophenotype associations were determined by linear regression analyses. There was an association between rs2070045-G allele and increased CSF-tau and more hippocampal atrophy. Additionally, haplotype-based analyses revealed an association between haplotype rs11218340-A/rs3824966-G/rs3824968-A and higher CSF-tau and CSF-tau phosphorylated at threonine 181. In conclusion, we found that SORL1 SNP rs2070045-G allele was related to CSF-tau and hippocampal atrophy, 2 endophenotype markers of AD, suggesting that SORL1 may be implicated in the downstream pathology in AD.
AB - We studied the association of SORL1 single-nucleotide polymorphisms genotypes with measures of pathology in patients with probable Alzheimer's disease (AD) using an endophenotype approach. We included (1) 133 patients from the German Dementia Competence Network (71 ± 8years; 50% females; Mini Mental State Examination [MMSE], 24 ± 3); (2) 83 patients from the Alzheimer's Disease Neuroimaging Initiative (75 ± 8years; 45% females; MMSE, 24 ± 2); and (3) 452 patients from the Amsterdam Dementia Cohort 66 ± 8years; 47% females; MMSE, 20 ± 5). As endophenotype markers we used cognitive tests, cerebrospinal fluid (CSF) biomarkers amyloid-beta, total tau (tau), tau phosphorylated at threonine 181, and hippocampal atrophy. We measured 19 SORL1 SNP alleles. Genotype-endophenotype associations were determined by linear regression analyses. There was an association between rs2070045-G allele and increased CSF-tau and more hippocampal atrophy. Additionally, haplotype-based analyses revealed an association between haplotype rs11218340-A/rs3824966-G/rs3824968-A and higher CSF-tau and CSF-tau phosphorylated at threonine 181. In conclusion, we found that SORL1 SNP rs2070045-G allele was related to CSF-tau and hippocampal atrophy, 2 endophenotype markers of AD, suggesting that SORL1 may be implicated in the downstream pathology in AD.
KW - Alzheimer's disease
KW - Endophenotypes
KW - SNPs
KW - SORL1
UR - http://www.scopus.com/inward/record.url?scp=84923631414&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2014.12.007
DO - 10.1016/j.neurobiolaging.2014.12.007
M3 - Article
C2 - 25659857
AN - SCOPUS:84923631414
VL - 36
SP - 1605.e13-1605.e20
JO - Neurobiology of Aging
JF - Neurobiology of Aging
SN - 0197-4580
IS - 3
ER -